Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628658 | 0.92 | LTB4R (0.44) | LTB4RPTGER2S1PR1S1PR3S1PR2 | |
| SCHEMBL5859870 | 0.88 | ALDH1A1 (0.47) | LTB4RPTGER2TBXA2R | |
| SCHEMBL1471110 | 0.88 | PTGER2 (0.43) | LTB4RPTGER2S1PR1S1PR3S1PR2 | |
| SCHEMBL1471697 | 0.85 | FFAR1 (0.43) | LTB4RPTGER2S1PR1S1PR3PTGER4 | |
| SCHEMBL9453929 | 0.82 | CYSLTR2 (0.61) | LTB4RPTGER2S1PR1S1PR3S1PR2 | |
| SCHEMBL12827664 | 0.79 | S1PR1 (0.67) | LTB4RPTGER2S1PR1S1PR3S1PR2 | |
| SCHEMBL1471279 | 0.78 | ALDH1A1 (0.48) | LTB4RPTGER2S1PR1S1PR3S1PR2 | |
| SCHEMBL11601260 | 0.78 | FFAR4 (0.65) | PTGER2FFAR4FFAR1TBXA2R | |
| SCHEMBL11602007 | 0.78 | FFAR4 (0.65) | PTGER2FFAR4FFAR1TBXA2R | |
| SCHEMBL1471504 | 0.77 | NR1H4 (0.51) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | claimed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | CRYZ, QDPR, GLRX3 | LTB4R 1952/4885PTGER2 1557/4885S1PR1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.